Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Mesenchymal Stem Cell Conditioned Medium for Neurological Diseases
jRCT1051250162Recruiting
- Sponsor
- Shin Yokohama Kato Clinic
- Start
- Dec 2025
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of human-derived mesenchymal stem cell conditioned medium in central nervous system conditions (CNSD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and 4 more, sponsored by Shin Yokohama Kato Clinic. Primary endpoints: Neurological function and disability scales (central nervous system), Peripheral nervous system function and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
human-derived mesenchymal stem cell conditioned medium
03
Conditions
central nervous system conditions (CNSD)amyotrophic lateral sclerosis (ALS)Parkinson's disease (PD)multiple sclerosis (MS)peripheral neuropathy
Beyond the preview
Go deeper on jRCT1051250162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051250162.